Finally, the current development of anti-CD73-based strategies and relative ongoing clinical trials in monotherapy or combination with immune checkpoint inhibitors as anti-PD-(L)1 mAbs or targeted therapies (EGFR-TKIs) in the treatment of advanced NSCLC are summarized in Table 4. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.